PAPADOPOULOS STELIOS — SEC Form 4 filings
SEC reporting owner CIK 1202098. 14 Form 4 filings on record with FilingPulse; latest filed 2026-05-29.
Transaction summary — filings shown
Covers all 14 filings on record, filed 2024-03-15 to 2026-05-29. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 4 legs across 3 filings — 147,945 shares, $6,214,307 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 27.
- Largest priced transaction: sale of 100,000 shares @ $43.55 ($4,355,000) in EXELIXIS, INC., filed 2025-11-13.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| EXELIXIS, INC. (EXEL) | Director | 6 | — | 4 legs · 147,945 sh · $6,214,307 | 9 |
| Regulus Therapeutics Inc. (RGLS) | Director | 5 | — | — | 15 |
| Ovid Therapeutics Inc. (OVID) | Director | 3 | — | — | 3 |
Form 4 filings — PAPADOPOULOS STELIOS
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-29 | 4 | EXELIXIS, INC. (EXEL) | Grant/award (A): 8,367 @ $0 | EDGAR |
| 2026-04-09 | 4 | Ovid Therapeutics Inc. (OVID) | Grant/award (A): 17,578 @ $2.56 | EDGAR |
| 2026-03-02 | 4 | Ovid Therapeutics Inc. (OVID) | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2025-11-13 | 4 | EXELIXIS, INC. (EXEL) | Sale (S): 100,000 @ $43.55 | EDGAR |
| 2025-06-27 | 4 | Regulus Therapeutics Inc. (RGLS) | Code (U): 976,253 · Disposition to issuer (D): 64,635 · Disposition to issuer (D): 4,650 (derivative) · Disposition to issuer (D): 2,325 (derivative) · Disposition to issuer (D): 4,000 (derivative) · Disposition to issuer (D): 9,000 (derivative) · +5 more | EDGAR |
| 2025-05-30 | 4 | EXELIXIS, INC. (EXEL) | Grant/award (A): 9,812 @ $0 | EDGAR |
| 2025-05-16 | 4 | EXELIXIS, INC. (EXEL) | Option exercise (M): 20,634 @ $19.77 · Sale (S): 20,634 @ $44.35 · Option exercise (M): 15,874 @ $20.50 · Sale (S): 15,874 @ $44.35 · Option exercise (M): 20,634 (derivative) @ $0 · Option exercise (M): 15,874 (derivative) @ $0 | EDGAR |
| 2025-04-30 | 4 | Regulus Therapeutics Inc. (RGLS) | Grant/award (A): 62,500 @ $0 | EDGAR |
| 2025-03-04 | 4 | Ovid Therapeutics Inc. (OVID) | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2024-06-04 | 4 | EXELIXIS, INC. (EXEL) | Grant/award (A): 18,838 @ $0 | EDGAR |
| 2024-05-22 | 4 | EXELIXIS, INC. (EXEL) | Option exercise (M): 11,686 @ $19.57 · Sale (S): 11,437 @ $21 · Option exercise (M): 11,686 (derivative) @ $0 | EDGAR |
| 2024-05-21 | 4 | Regulus Therapeutics Inc. (RGLS) | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2024-05-17 | 4 | Regulus Therapeutics Inc. (RGLS) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-03-15 | 4 | Regulus Therapeutics Inc. (RGLS) | Grant/award (A): 250,000 @ $1.60 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1202098 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →